Recordati earnings are due November 10 for Recordati stock

Published on 10/27/2026 at 18:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached EUR 697.20 million in Q2 2026. Recordati stock costs EUR 52.70 on October 27, 2026, down 0.57 percent versus Xetra close.

Reporting date and revenue

Recordati earnings are due on November 10, 2026.
Second-quarter revenue reached EUR 697.20 million versus EUR 681.55 million estimated.
Recordati stock was trading at EUR 52.70 at Lang & Schwarz on October 27, 2026, down 0.57 percent versus the Xetra close.

Recordati, IT0003828271, Illustration mit AI erstellt.

Recordati (IT0003828271) has its next earnings report scheduled for November 10, 2026, while its second-quarter revenue reached EUR 697.20 million. TradingView lists the November 10 reporting date and the quarterly revenue figure. The stock was trading at EUR 52.70 at Lang & Schwarz on October 27, 2026 at 5:53 p.m. CEST, down 0.57 percent versus the Xetra close of October 27, 2026 at EUR 53.00.

Revenue beat the estimate

The second-quarter revenue figure stood above the EUR 681.55 million estimate listed by TradingView, a difference of EUR 15.65 million or 2.30 percent. That comparison gives the November report a clear financial benchmark, even as the takeover process remains part of the stock's trading backdrop.

Recordati describes itself as a global pharmaceutical company with more than 4,700 employees and activities in around 150 countries. Its portfolio covers medicines for common diseases and rare diseases, giving the quarterly revenue figure a broad operating base.

Stock sits below the close

The EUR 52.70 Lang & Schwarz price was EUR 0.30 below the EUR 53.00 Xetra close, equivalent to a 0.57 percent decline. The move is modest in percentage terms, but the level is close to the EUR 53.00 consideration associated with the takeover process.

Recordati's next earnings date is November 10, 2026. The company reported its first-half 2026 results on July 29, 2026, according to its investor-relations presentation archive, so the November release will provide the next scheduled operating update.

What the next report will clarify

The upcoming report will give investors a fresh comparison with the second-quarter revenue of EUR 697.20 million and the EUR 681.55 million estimate. Recordati's valuation will also be judged against the offer-related price level and the company's ability to maintain revenue growth through its common-disease and rare-disease businesses.

Price and reporting date

Recordati was trading at EUR 52.70 at Lang & Schwarz on October 27, 2026 at 5:53 p.m. CEST, after the Xetra close of October 27, 2026 at EUR 53.00. The next scheduled earnings report is November 10, 2026. The further course of trading is shown by the continuously updated real-time quote of Recordati stock.